{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to the number of events during the observation period.","groupId":"OG000","lowerLimit":"5.1","upperLimit":"NA","value":"6.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"Time to hematological relapse was measured for participants in remission during the core study (the time from the first infusion through 30 days after the last infusion), from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their date of death.\n\nHematological relapse is defined as:\n\n* proportion of blasts in bone marrow \\> 5% after documented CR/CRh\\* or\n* blasts in peripheral blood after documented CR/CRh\\*.\n\nTime to hematological relapse was analyzed by Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"MEDIAN","populationDescription":"Participants who reached complete remission or complete remission with partial hematological recovery during the core study.","reportingStatus":"POSTED","timeFrame":"Up to the data cut-off date of 10 October 2013; median observation time was 8.0 months.","title":"Time to Hematological Relapse (Duration of Response)","type":"SECONDARY","unitOfMeasure":"months"}